Austin Aerts Sells 5,440 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,440 shares of Sera Prognostics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $11,315.20. Following the transaction, the chief financial officer directly owned 303,227 shares of the company’s stock, valued at approximately $630,712.16. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Price Performance

Shares of NASDAQ SERA opened at $1.93 on Friday. Sera Prognostics, Inc. has a 1 year low of $1.50 and a 1 year high of $4.09. The stock has a market cap of $75.58 million, a P/E ratio of -2.97 and a beta of 0.94. The firm has a 50-day moving average of $2.03 and a 200 day moving average of $2.54.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.07 million. Research analysts expect that Sera Prognostics, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of large investors have recently made changes to their positions in SERA. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $31,000. Arkadios Wealth Advisors purchased a new position in shares of Sera Prognostics during the first quarter valued at approximately $25,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Sera Prognostics during the third quarter valued at approximately $38,000. Lido Advisors LLC purchased a new position in shares of Sera Prognostics during the third quarter valued at approximately $68,000. Finally, Cetera Investment Advisers purchased a new position in shares of Sera Prognostics during the fourth quarter valued at approximately $74,000. 54.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. Craig Hallum initiated coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.